Nuvo Pharmaceuticals Inc NRIFF

RE: RE: RE: RE: From outside, looking in (not so b

[3dollar]

After sleeping on it couple more thoughts came to mind.  WF-10 is dead and or years and years away from being an applicable treatment in any one field.  I can't believe Keeler is still fighting for her "dismissal"money knowing that she costs the company in excess of $50,000,0000 with the acquisition of WF-10.

I don't want to harp but the Canadian Pennsaid sales are an abomination....this product is dead in Canada and that is shameful.  I'd love to know what the initial Voltaren Gel sales have been??  I'm guessing significantly better than anything Pennsaid has ever done.

Although I have been around a long time with this stock I think we'd all be foolish to assume that the current price is a direct result of the warrant program.  Just maybe the current share price is a reflection of the overall market's perception of this company's ability to get anything done.  There are a lot of legacy shareholders out there who have been burned over the years and to this date we still have nothing tangible to hang our hat on with this company.  Current management has failed ot deliver on its promise of "transparency" and I seriously doubt if they have done anything on either "street" to inspire long term confidence for a return on investment.

The more and more I think about this i draw the conclusion that management should be doing one thing and one thing only.......find the best possible deal and sell 100% control of the company.  The MD&A crystalizes the many hurdles that need to be cleared pre and post FDA approval.  Why would a potential partner sign up for $100's of millions in licensing and royalty fees if they could buy the company outright for a few pennies more??  With dilution of 471,000,000 (includes all options and warrants still outstanding) shares outstanding what would a fair market price be for this company??  Considering the market conditions who here wouldn't take a buck a share right now??  With a strong Canadian $$ it would cost a US buyer somewhere around $380m US$ to take this off our hands.  That seems to be a reasonable price to pay for a soon to be FDA approved product and technology that could potentially revolutionize drug delivery.

The longer Nuvo remains an island in the big bad world of biotechnology the greater the chance today's investor loses it all.  Don't mean to be negative but am realistic about our chances of long term success.  Let's get bought and take all of the guesswork out of play.